PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
HALO vs. HIMS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between HALO and HIMS is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

HALO vs. HIMS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Halozyme Therapeutics, Inc. (HALO) and Hims & Hers Health, Inc. (HIMS). The values are adjusted to include any dividend payments, if applicable.

0.00%100.00%200.00%300.00%400.00%500.00%600.00%SeptemberOctoberNovemberDecember2025February
263.33%
360.10%
HALO
HIMS

Key characteristics

Sharpe Ratio

HALO:

1.23

HIMS:

2.37

Sortino Ratio

HALO:

1.77

HIMS:

2.71

Omega Ratio

HALO:

1.28

HIMS:

1.38

Calmar Ratio

HALO:

1.33

HIMS:

4.37

Martin Ratio

HALO:

3.82

HIMS:

11.39

Ulcer Index

HALO:

12.70%

HIMS:

20.70%

Daily Std Dev

HALO:

39.49%

HIMS:

99.63%

Max Drawdown

HALO:

-74.26%

HIMS:

-87.29%

Current Drawdown

HALO:

-8.18%

HIMS:

-34.41%

Fundamentals

Market Cap

HALO:

$7.11B

HIMS:

$9.18B

EPS

HALO:

$3.43

HIMS:

$0.53

PE Ratio

HALO:

16.82

HIMS:

78.00

PEG Ratio

HALO:

-2.50

HIMS:

3.96

Total Revenue (TTM)

HALO:

$1.02B

HIMS:

$1.48B

Gross Profit (TTM)

HALO:

$820.38M

HIMS:

$1.13B

EBITDA (TTM)

HALO:

$646.55M

HIMS:

$72.93M

Returns By Period

In the year-to-date period, HALO achieves a 23.72% return, which is significantly lower than HIMS's 86.48% return.


HALO

YTD

23.72%

1M

4.84%

6M

-7.36%

1Y

43.88%

5Y*

23.63%

10Y*

14.23%

HIMS

YTD

86.48%

1M

32.77%

6M

206.11%

1Y

243.67%

5Y*

35.47%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

HALO vs. HIMS — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HALO
The Risk-Adjusted Performance Rank of HALO is 8181
Overall Rank
The Sharpe Ratio Rank of HALO is 8484
Sharpe Ratio Rank
The Sortino Ratio Rank of HALO is 7777
Sortino Ratio Rank
The Omega Ratio Rank of HALO is 8282
Omega Ratio Rank
The Calmar Ratio Rank of HALO is 8585
Calmar Ratio Rank
The Martin Ratio Rank of HALO is 7878
Martin Ratio Rank

HIMS
The Risk-Adjusted Performance Rank of HIMS is 9494
Overall Rank
The Sharpe Ratio Rank of HIMS is 9696
Sharpe Ratio Rank
The Sortino Ratio Rank of HIMS is 9090
Sortino Ratio Rank
The Omega Ratio Rank of HIMS is 9090
Omega Ratio Rank
The Calmar Ratio Rank of HIMS is 9898
Calmar Ratio Rank
The Martin Ratio Rank of HIMS is 9494
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

HALO vs. HIMS - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Hims & Hers Health, Inc. (HIMS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for HALO, currently valued at 1.23, compared to the broader market-3.00-2.00-1.000.001.002.003.001.232.37
The chart of Sortino ratio for HALO, currently valued at 1.77, compared to the broader market-4.00-2.000.002.004.001.772.71
The chart of Omega ratio for HALO, currently valued at 1.28, compared to the broader market0.501.001.502.001.281.38
The chart of Calmar ratio for HALO, currently valued at 1.33, compared to the broader market0.001.002.003.004.005.006.001.334.37
The chart of Martin ratio for HALO, currently valued at 3.82, compared to the broader market-5.000.005.0010.0015.0020.0025.003.8211.39
HALO
HIMS

The current HALO Sharpe Ratio is 1.23, which is lower than the HIMS Sharpe Ratio of 2.37. The chart below compares the historical Sharpe Ratios of HALO and HIMS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.006.00SeptemberOctoberNovemberDecember2025February
1.23
2.37
HALO
HIMS

Dividends

HALO vs. HIMS - Dividend Comparison

Neither HALO nor HIMS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

HALO vs. HIMS - Drawdown Comparison

The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum HIMS drawdown of -87.29%. Use the drawdown chart below to compare losses from any high point for HALO and HIMS. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-8.18%
-34.41%
HALO
HIMS

Volatility

HALO vs. HIMS - Volatility Comparison

The current volatility for Halozyme Therapeutics, Inc. (HALO) is 4.40%, while Hims & Hers Health, Inc. (HIMS) has a volatility of 54.10%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than HIMS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%SeptemberOctoberNovemberDecember2025February
4.40%
54.10%
HALO
HIMS

Financials

HALO vs. HIMS - Financials Comparison

This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Hims & Hers Health, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab